A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Pimodivir in Adult Subjects

The purpose of this study is to evaluate the pharmacokinetics (PK) of pimodivir after a single oral dose of 600 milligrams (mg) in adult participants with severe renal impairment who are not on dialysis and in adult participants with end-stage renal disease (ESRD) who are not yet on dialysis compared to adult participants with normal renal function (Part A). Optionally, to evaluate the PK in adult participants with mild and/or moderate renal impairment compared to adult participants with normal renal function (Part B).

Start Date02 Jul 2019

Sponsor / Collaborator

Janssen-Cilag International NV

NCT03816631 / CompletedPhase 1

A Phase 1, Open-label, Single-dose Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Orally Administered Pimodivir in Adult Subjects

The purpose is to evaluate the pharmacokinetics (PK) of a single oral dose of 600 milligram (mg) pimodivir in adult participants with impaired hepatic function compared to adult participants with normal hepatic function.

Start Date28 May 2019

Sponsor / Collaborator

Janssen-Cilag International NV

NCT03768609 / CompletedPhase 1

A Randomized, Open-label, Single-dose, 2-period, 2-sequence, Crossover, Phase 1 Study to Evaluate the Effect of Cyclosporine, a P-glycoprotein, Breast Cancer Resistance Protein, and Organic-anion-transporting Polypeptide Inhibitor, on the Pharmacokinetics of Pimodivir in Healthy Adult Subjects

The purpose of this study is to evaluate the effect of a single oral dose of cyclosporine on the pharmacokinetics of a single oral dose of pimodivir when coadministered to healthy adult participants under fasted conditions.

Start Date06 Dec 2018

Sponsor / Collaborator

Janssen-Cilag International NV

100 Clinical Results associated with Pimodivir

100 Translational Medicine associated with Pimodivir

100 Patents (Medical) associated with Pimodivir

Literatures (Medical) associated with Pimodivir

01 Jun 2023·Antiviral therapy

Genotypic and phenotypic characterization of influenza A viral variants in study participants treated with pimodivir in the phase 2b TOPAZ study

Article

Author: Leopold, Lorant ; Van Dromme, Ilse ; De Meyer, Sandra ; van Duijnhoven, Wilbert ; Anderson, David ; Vingerhoets, Johan

Background:

Pimodivir is a first-in-class polymerase basic protein 2 (PB2) subunit inhibitor of the influenza A polymerase complex. The randomized double-blinded placebo-controlled phase 2b TOPAZ study demonstrated antiviral activity and safety of twice daily pimodivir alone (300 mg, 600 mg) or in combination with oseltamivir (pimodivir 600 mg, oseltamivir 75 mg) in adult study participants with acute uncomplicated influenza A. The detailed genotypic and phenotypic characterization of viral variants observed in this study are reported.

Methods:

Population sequencing of PB2 and neuraminidase genes, and phenotypic susceptibility testing, were performed using baseline and last virus-positive post-baseline nasal swab samples.

Results:

Sequencing of baseline samples in 206 of 223 (92.4%) randomized study participants with confirmed influenza A infection identified no polymorphisms at any predefined PB2 positions of interest for pimodivir and no phenotypic reduced susceptibility to pimodivir was observed. Post-baseline sequencing data for 105/223 (47.1%) participants identified emergence of PB2 mutations at amino acid positions of interest in 10 (9.5%) participants (pimodivir 300 mg: n = 3; 600 mg: n = 6; combination: n = 1; placebo: n = 0) and included positions S324, F325, S337, K376, T378, and N510. These emerging mutations were typically associated with decreased pimodivir susceptibility, but not viral breakthrough. No reduced phenotypic susceptibility was observed in the one (1.8%) participant with emerging PB2 mutations from the pimodivir plus oseltamivir group.

Conclusions:

Participants with acute uncomplicated influenza A treated with pimodivir in the TOPAZ study infrequently developed reduced susceptibility to pimodivir and combining pimodivir with oseltamivir further decreased the risk of reduced susceptibility development.

12 Aug 2022·JOURNAL OF INFECTIOUS DISEASESQ2 · MEDICINE

A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study

Q2 · MEDICINE

Article

Author: Van Dromme, Ilse ; Anderson, David ; Deleu, Sofie ; Kosoglou, Teddy ; Torres, Antoni ; Ison, Michael G ; Wilburn, John M ; Leopold, Lorant ; Vingerhoets, Johan ; O’Neil, Brian ; Hallouin-Bernard, Marie Charlotte ; Nilsson, Anna C ; van Duijnhoven, Wilbert ; Rossenu, Stefaan

Abstract:

Background:

Both the elderly and individuals with comorbidities are at increased risk of developing influenza-related complications. Novel influenza antivirals are required, given limitations of current drugs (eg, resistance emergence and poor efficacy). Pimodivir is a first-in-class antiviral for influenza A under development for these patients.

Methods:

Hospitalized patients with influenza A infection were randomized 2:1 to receive pimodivir 600 mg plus oseltamivir 75 mg or placebo plus oseltamivir 75 mg twice daily for 7 days in this phase 2b study. The primary objective was to compare pimodivir pharmacokinetics in elderly (aged 65–85 years) versus nonelderly adults (aged 18–64 years). Secondary end points included time to patient-reported symptom resolution.

Results:

Pimodivir pharmacokinetic parameters in nonelderly and elderly patients were similar. Time to influenza symptom resolution was numerically shorter with pimodivir (72.45 hours) than placebo (94.15 hours). There was a lower incidence of influenza-related complications in the pimodivir group (7.9%) versus placebo group (15.6%). Treatment was generally well tolerated.

Conclusions:

No apparent relationship was observed between pimodivir pharmacokinetics and age. Our data demonstrate the need for a larger study of pimodivir in addition to oseltamivir to test whether it results in a clinically significant decrease in time-to-influenza-symptom alleviation and/or the frequency of influenza complications.

Clinical trials registration:

NCT02532283.

01 Jan 2022·Computational and structural biotechnology journal

Virus-host interaction analysis in colorectal cancer identifies core virus network signature and small molecules

Article

Author: A V S, Sai Krishna ; Donakonda, Sainitin ; Sinha, Swati

Colorectal cancer (CRC) is a significant contributor to cancer-related deaths caused by an unhealthy lifestyle. Multiple studies reveal that viruses are involved in colorectal tumorigenesis. The viruses such as Human Cytomegalovirus (HCMV), Human papillomaviruses (HPV16 & HPV18), and John Cunningham virus (JCV) are known to cause colorectal cancer. The molecular mechanisms of cancer genesis and maintenance shared by these viruses remain unclear. We analysed the virus-host networks and connected them with colorectal cancer proteome datasets and extracted the core shared interactions in the virus-host CRC network. Our network topology analysis identified prominent virus proteins RL6 (HCMV), VE6 (HPV16 and HPV18), and Large T antigen (JCV). Sequence analysis uncovered short linear motifs (SLiMs) in each viral target. We used these targets to identify the antiviral drugs through a structure-based virtual screening approach. This analysis highlighted that temsavir, pimodivir, famotine, and bictegravir bind to each virus protein target, respectively. We also assessed the effect of drug binding using molecular dynamic simulations, which shed light on the modulatory effect of drug molecules on SLiM regions in viral targets. Hence, our systematic screening of virus-host networks revealed viral targets, which could be crucial for cancer therapy.

News (Medical) associated with Pimodivir

25 Mar 2015

·www.bioportfolio.com

H3N2 Infection - Pipeline Review, H1 2015

Recently added to the BioPortfolio report store, H3N2 Infection - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-02-23. This 62-page report is available in PDF from $2000. H3N2 Infection - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘H3N2 Infection - Pipeline Review, H1 2015’, provides an overview of the H3N2 Infection’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H3N2 Infection and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of H3N2 Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H3N2 Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H3N2 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H3N2 Infection pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of… Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 H3N2 Infection Overview 7 Therapeutics Development 8 Pipeline Products for H3N2 Infection - Overview 8 Pipeline Products for H3N2 Infection - Comparative Analysis 9 H3N2 Infection - Therapeutics under Development by Companies 10 H3N2 Infection - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 H3N2 Infection - Products under Development by Companies 14 H3N2 Infection - Companies Involved in Therapeutics Development 15 AlphaVax, Inc. 15 Colby Pharmaceutical Company 16 Crucell N.V. 17 Cure Lab, Inc. 18 Inovio Pharmaceuticals, Inc. 19 Johnson & Johnson 20 NanoViricides, Inc. 21 REPLICor Inc. 22 Takeda Pharmaceutical Company Limited 23 Vaxart, Inc. 24 H3N2 Infection - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Combination Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 Aspidasept - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 AVX-502 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 bordetella pertussis [strain BPZE1] vaccine - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 C-05 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 CLVax-1.0 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 CR-9114 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Gamma-Flu - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ID-38 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 influenza [H3N2] vaccine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 influenza vaccine - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 JVRS-100 + influenza [H1N1/H3N2] vaccine - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 NVINF-1 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 NVINF-2 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 REP-9 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 seasonal influenza [H3N2] vaccine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 VX-787 … For more information open H3N2 Infection - Pipeline Review, H1 2015. SKU: GMDHC6284IDB

First in ClassVaccine

100 Deals associated with Pimodivir

External Link

KEGG	Wiki	ATC	Drug Bank
D11287	Pimodivir	-	DB14974

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza A virus infection	Phase 3	US	Janssen Research & Development LLC	03 Jan 2018
Influenza A virus infection	Phase 3	CN	Janssen Research & Development LLC	03 Jan 2018
Influenza A virus infection	Phase 3	AR	Janssen Research & Development LLC	03 Jan 2018
Influenza A virus infection	Phase 3	AU	Janssen Research & Development LLC	03 Jan 2018
Influenza A virus infection	Phase 3	AT	Janssen Research & Development LLC	03 Jan 2018
Influenza A virus infection	Phase 3	BE	Janssen Research & Development LLC	03 Jan 2018
Influenza A virus infection	Phase 3	BR	Janssen Research & Development LLC	03 Jan 2018
Influenza A virus infection	Phase 3	BG	Janssen Research & Development LLC	03 Jan 2018
Influenza A virus infection	Phase 3	CA	Janssen Research & Development LLC	03 Jan 2018
Influenza A virus infection	Phase 3	CL	Janssen Research & Development LLC	03 Jan 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03381196 (CTgov)	Phase 3	Influenza A virus infection	553	Pimodivir (Pimodivir + SOC)	omntuqlknd(figfpitmxu) = rzgafwzpju yxbmobgvzs (yhrclnvhev, jjnqijzjvt - wconpqtgcb) View more	-	24 May 2021
				Placebo (Placebo + SOC)	omntuqlknd(figfpitmxu) = ltwldwzblv yxbmobgvzs (yhrclnvhev, tszyihwljf - sxxromgusk) View more
NCT03376321 (CTgov)	Phase 3	Influenza A virus infection	334	Pimodivir (Pimodivir + SOC)	xibayxhgcl(vzooynnmih) = dzrjuyzmhf sueusebscp (ngcjznsoip, xoqnwpckuu - ycjgscrqgl) View more	-	14 Apr 2021
				Placebo (Placebo + SOC)	xibayxhgcl(vzooynnmih) = ujvpejvzbt sueusebscp (ngcjznsoip, wxfgarjfwm - akwvtxxnzt) View more
NCT02532283 (CTgov)	Phase 2	Influenza A virus infection	102	oseltamivir+pimodivir (Elderly Adults (65 to Less Than or Equal to [<=] 85 Years))	ubqqvskrno(gpqbylnbry) = egjsfypjzd ezjbhrbafq (fbytniyaqc, sdeslzclqh - lscwivphkk) View more	-	27 Mar 2020
				oseltamivir+pimodivir (Non-elderly Adults (18 to <=64 Years))	ubqqvskrno(gpqbylnbry) = qedjepohlt ezjbhrbafq (fbytniyaqc, ivsxqsgeqd - kophroagri) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis